Evaluation of Contact Phase Activation During Hemodialysis

Exclusion Criteria

• •Use of vitamin K antagonists or novel oral anticoagulant therapy.
• •Use of chronic heparin treatment, UFH or LMWH.
• •Use of clopidogrel.
• •Use of ACE-inhibitors.
• •Known allergy against one of the dialysis membranes used during this study (PMMA: BKU®, Toray; PS: Phylter®, Bellco; AN69ST: Evodial®, Gambro).
• •Known heparin-induced trombopenia type 2.
• •Active infection and/or ongoing systemic antimicrobial treatment.
• •Presence of central venous catheter, tunnelled or non-tunnelled and/or AV graft.
• •Hospitalized patients.
• •Planned surgery during study period.
• •Mean Qb of \<300ml/min during one of the last 3 dialysis sessions before inclusion.
• •Vascular access dysfunction defined as (a) known AV access outflow tract stenosis, (b) planned vascular access intervention, (c) planned vascular access conversion.
• •Planned conversion of dialysis modality during study period.